Scientific Data (Aug 2024)

Reinterpretation of prostate cancer pathology by Appl1, Sortilin and Syndecan-1 biomarkers

  • Jessica M. Logan,
  • Carmela Martini,
  • Alexandra Sorvina,
  • Ian R. D. Johnson,
  • Robert D. Brooks,
  • Maria C. Caruso,
  • Chelsea Huzzell,
  • Courtney R. Moore,
  • Litsa Karageorgos,
  • Lisa M. Butler,
  • Prerna Tewari,
  • Sarita Prabhakaran,
  • Shane M. Hickey,
  • Sonja Klebe,
  • Hemamali Samaratunga,
  • Brett Delahunt,
  • Kim Moretti,
  • John J. O’Leary,
  • Douglas A. Brooks,
  • Ben S.-Y. Ung

DOI
https://doi.org/10.1038/s41597-024-03696-0
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 10

Abstract

Read online

Abstract The diagnosis of prostate cancer using histopathology is reliant on the accurate interpretation of prostate tissue sections. Current standards rely on the assessment of Haematoxylin and Eosin (H&E) staining, which can be difficult to interpret and introduce inter-observer variability. Here, we present a digital pathology atlas and online resource of prostate cancer tissue micrographs for both H&E and the reinterpretation of samples using a novel set of three biomarkers as an interactive tool, where clinicians and scientists can explore high resolution histopathology from various case studies. The digital pathology prostate cancer atlas when used in conjunction with the biomarkers, will assist pathologists to accurately grade prostate cancer tissue samples.